900912:SSEShanghai Waigaoqiao Free Trade Zone Group Co., Ltd. Class B Analysis
Data as of 2026-03-15 - not real-time
$0.69
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Shanghai Waigaoqiao Free Trade Zone Group trades at a trailing PE of 8.6, far below the industry average of 29.1, and a price‑to‑book of 0.43, suggesting a strong valuation discount. However, the company’s revenue has contracted by 34% year‑over‑year, operating cash flow is negative, and debt‑to‑equity sits at a staggering 142, raising concerns about financial stability. The stock offers an attractive 7.07% dividend yield, but the unsustainable cash‑flow profile and a payout ratio above 60% cast doubt on future payments. Technically, the price sits just above the nearest support at 0.681 and below the 200‑day SMA of 0.727, with a neutral RSI around 51 and a bearish MACD histogram, indicating limited upside in the short run.
Overall, the equity appears markedly undervalued from a pure price‑multiple perspective, yet the combination of declining earnings, high leverage, and dividend sustainability concerns tempers enthusiasm, especially for longer horizons.
Overall, the equity appears markedly undervalued from a pure price‑multiple perspective, yet the combination of declining earnings, high leverage, and dividend sustainability concerns tempers enthusiasm, especially for longer horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with limited upside
- Bearish MACD histogram
- Low beta indicating limited price volatility
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Significant valuation discount (PE 8.6 vs industry 29)
- High debt load and negative cash flow
- Attractive dividend yield but sustainability concerns
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Persistent revenue decline and weak profitability
- Elevated leverage (debt‑to‑equity >140)
- Uncertain dividend continuation amid cash‑flow deficits
Key Metrics & Analysis
Financial Health
Revenue Growth-34.40%
Profit Margin10.36%
P/E Ratio8.6
ROE4.84%
ROA1.11%
Debt/Equity142.33
P/B Ratio0.4
Op. Cash Flow$-1241693696
Free Cash Flow$-617462784
Industry P/E29.1
Technical Analysis
TrendNeutral
RSI51.5
Support$0.68
Resistance$0.70
MA 20$0.69
MA 50$0.69
MA 200$0.73
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
GradeUndervalued
TypeValue
Dividend Yield7.07%
Risk Assessment
Beta0.05
Volatility7.94%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.